Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 12,352 |
|
|||||
| News | - | ||||||
| Day High | 6.74 | Low High |
|||||
| Day Low | 5.6201 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Vaccinex Inc | VCNX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.1011 | -1.70% | 5.83 | 18:45:33 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 6.355 | 5.6201 | 6.74 | 5.83 | 5.9311 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 290 | 12,352 | US$ 6.37 | US$ 78,642 | - | 4.432 - 100.80 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:45:26 | 10 | US$ 6.15 | USD |
Vaccinex Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 6.8M | 1.17M | - | 570k | -20.25M | -17.36 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Vaccinex News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/02/2024 | 07:30 | GlobeNewswire Inc. | Vaccinex Reports 2023 Financial Results and Provides.. |
| 3/27/2024 | 07:30 | GlobeNewswire Inc. | Vaccinex, Inc. Announces $1.5 Million Registered Direct.. |
| 3/04/2024 | 15:19 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/21/2024 | 09:10 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/21/2024 | 07:00 | GlobeNewswire Inc. | Vaccinex Announces Multiple New Agreements for Access to.. |
| 2/15/2024 | 07:06 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/15/2024 | 07:00 | GlobeNewswire Inc. | Vaccinex, Inc. Announces Reverse Stock Split |
| 2/13/2024 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/13/2024 | 15:15 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of.. |
| 2/12/2024 | 15:22 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of.. |
| 2/09/2024 | 15:34 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/09/2024 | 15:32 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VCNX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.63 | 6.74 | 4.50 | 5.19 | 6,667 | 1.20 | 25.92% |
| 1 Month | 7.39 | 7.59 | 4.432 | 5.91 | 10,371 | -1.56 | -21.11% |
| 3 Months | 8.40 | 13.02 | 4.432 | 9.98 | 65,637 | -2.57 | -30.60% |
| 6 Months | 14.00 | 15.9096 | 4.432 | 10.32 | 74,414 | -8.17 | -58.36% |
| 1 Year | 81.90 | 100.80 | 4.432 | 29.91 | 279,711 | -76.07 | -92.88% |
| 3 Years | 516.60 | 688.80 | 4.432 | 222.52 | 328,127 | -510.77 | -98.87% |
| 5 Years | 1,415.40 | 2,568.30 | 4.432 | 694.63 | 587,269 | -1,409.57 | -99.59% |
Vaccinex Description
| Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's product pipeline includes pepinemab (VX15), which targets Huntington's Disease (HD) and non-small cell lung cancer (NSCLC) and also neurodegenerative disorders; VX5 Autoimmune for the treatment of MS and potentially for other autoimmune disorder; and others. |
